Drug Profile
Research programme: heat shock protein 70 inhibitors - ALS Biopharma
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator ALS Biopharma
- Class Biological proteins; Small molecules
- Mechanism of Action HSP70 heat shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Amyotrophic lateral sclerosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA
- 25 Jun 2010 Preclinical trials in Alzheimer's disease in USA (unspecified route)